Recent advances in the discovery and evaluation of fatty acid amide hydrolase inhibitors

Expert Opinion on Drug Discovery

Volumn 5, Issue 10, 2010, Pages 961-993

  Deng, Hongfeng ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

keto heterocycles; 2 arachodonyl glycerol; Analgesia; AnandamiD.E.; Carbamates; Endocannabinoid; FAAH; FAAH inhibitor; Fatty acid amides; Piperidine ureas

Indexed keywords

7 PHENYL 1 [5 (2 PYRIDINYL) 2 OXAZOLYL] 1 HEPTANONE; ANANDAMIDE; BETA LACTAM; BMS 1; BORONIC ACID DERIVATIVE; CANNABINOID 1 RECEPTOR AGONIST; CANNABIS; CARBAMIC ACID; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; JNJ 1661010; JZL 195; KETONE; LY 2183240; NABILONE; OLEAMIDE; PF 3845; PF 622; PF 750; PIPERIDINE; PLACEBO; SEROTONIN; SRR 411298; SSR 411298; ST 3987; ST 4020; ST 4070; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 524; US 2007004741; VER 156084; WO 2006054652; WO 2006074025; WO 2006088075; WO 2007020888; WO 2007070892; WO 2008023720; WO 2008145839; WO 2008145843; WO 2008153752; WO 2009011904; WO 2009084970; WO 2009105220; WO 2009109743; WO 2009117444; WO 2009151991; WO 2009152025; WO 2010007966; WO 2010010288; WO 2010017079; WO 2010039186;

ALLODYNIA; ANXIETY; BIOLOGICAL ACTIVITY; CARDIOVASCULAR DISEASE; CATALYSIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEPRESSION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; ENTERITIS; HUMAN; HYDROLYSIS; INFLAMMATION; MAJOR DEPRESSION; MEDICAL DECISION MAKING; MENTAL DISEASE; METABOLIC DISORDER; NEUROPATHIC PAIN; NONHUMAN; PAIN; POSTOPERATIVE NAUSEA AND VOMITING; PRIORITY JOURNAL; REPRODUCTION; REVIEW; SUICIDAL IDEATION;

EID: 77956862617     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2010.513378     Document Type: Review

References (128)

1. Cravatt BF, Prospero-Garcia O, Siuzdak G, et al. Chemical characterization of a family of brain lipids that induce sleep. Science 1995;268:1506-1509
2. Cravatt BF, Giang DK, Mayfield SP, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996;384:83-87
3. Mechoulam R, Shov Y, Hashish I. Structure of cannabidiol. Tetrahedron 1963;19:2073-2078
4. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646-1647
5. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949
6. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmocology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161-202
7. Piomelli D. The molecular logic of endocannabinoid signaling. Nat Rev Neurosci 2003;4:873-884
8. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008;7:438-455
9. Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001;98:9371-9376
10. McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 2005;74:411-432
11. Ahn K, Mckinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008;108:1687-1707
12. Patricelli MP, Lashuel HA, Giang DK, et al. Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase: identification of the transmembrane domain as a site for oligomerization. Biochemistry 1998;37:15177-15187
13. Wei BQ, Mikkelsen TS, McKinney MK, et al. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 2006;281:36569-36578
14. Patricelli MP, Cravatt BF. Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism. Biochemistry 1999;38:14125-14130
15. Lodola A, Mor M, Hermann JC, et al. QM/MM modeling of oleamide hydrolysis in fatty acid amide hydrolase (FAAH) reveals a new mechanism of nucleophile activation. Chem Commun 2005;35:4399-4401
16. Bracey MH, Hanson MA, Masuda KR, et al. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 2002;298:1793-1796
17. Mileni M, Johnson DS, Wang Z, et al. Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc Natl Acad Sci USA 2008;105:12820-12824
18. Ahn K, Johnson DS, Mileni M, et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 2009;16:411-420
19. Mileni M, Garfunkle J, DeMartino JK, et al. Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures. J Am Chem Soc 2009;131:10497-10506
20. Mileni M, Garfunkle J, Ezzili C, et al. X-ray crystallographic analysis of alpha-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase. J Med Chem 2010;53:230-240
21. Fu J, Gaetani S, Oveisi F, et al. Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR alpha. Nature 2003;425:90-93
22. Thabuis C, Tissot-Favre D, Bezelgues JB, et al. Biological functions and metabolism of oleoylethanolamide. Lipids 2008;43:887-894
23. LoVerme J, La Rana G, Russo R, et al. The search for the palmitoylethanolamide receptor. Life Sci 2005;77:1685-1698
24. Ryberg E, Larsson N, Sjogren S, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007;152:1092-1101
25. Costa B, Comelli F, Bettoni I, et al. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPAR gama receptors and neurotrophic factors. Pain 2008;139:541-550
26. Saghatelian A, McKinney MK, Bandell M, et al. A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry 2006;45:9007-9015
27. Bradshaw HB, Rimmerman N, Hu S-J, et al. Novel endogenous N-acyl glycines: identification and characterization. Vitamins and hormones 2009;81:191-205
28. Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 1998;422:69-73
29. Dinh TP, Carpenter D, Leslie FM, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci USA 2002;99:10819-10824
30. Lambert DM, Fowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 2005;48:5059-5087
31. Vandevoorde S. Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors. Curr Top Med Chem 2008;8:247-267
32. Seierstad M, Breitenbucher JG. Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem 2008;51:7327-7343
33. Ahn K, Johnson DS, Cravatt BF. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin Drug Discov 2009;4:763-784
34. Petrosino S, Di Marzo V. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Invest Drugs 2010;11:51-62
35. Minkkila A, Saario SM, Nevalainen T. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors. Curr Top Med Chem 2010;10:828-858
36. Bisogno T, Melck D, De Petrocellis L, et al. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochim Biophys Res Commun 1998;248:515-522
37. Maione S, De Petrocellis L, De Novellis V, et al. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 2007;150:766-781
38. Costa B, Bettoni I, Petrosino S, et al. The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. Pharm Res 2010;61:537-546
39. Koutek B, Prestwich GD, Howlett AC, et al. Inhibitors of arachidonoyl ethanolamide hydrolysis. J Biol Chem 1994;269:22937-22940
40. Patterson JE, Ollmann IR, Cravatt BF, et al. Inhibition of oleamide hydrolase catalyzed hydrolysis of the endogenous sleep-inducing lipid cis-9-octadecenamide. J Am Chem Soc 1996;118:5938-5945
41. Boger DL, Sato H, Lerner AE, et al. Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition. Bioorg Med Chem Lett 1999;9:265-270
42. Boger DL, Sato H, Lerner AE, et al. Exceptionally potent inhibitors of fatty acid amide hydrolase:the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 2000;97:5044-5049
43. Boger DL, Miyauchi H, Hedrick MP. alpha-Keto heterocycle inhibitors of fatty acid amide hydrolase: carbonyl group modification and alpha-substitution. Bioorg Med Chem Lett 2001;11:1517-1520
44. Boger DL, Miyauchi H, Du W, et al. Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem 2005;48:1849-1856
45. Kimball FS, Romero FA, Ezzili C, et al. Optimization of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem 2008;51:937-947
46. DeMartino JK, Garfunkle J, Hochstatter DG, et al. Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: potent and selective inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett 2008;18:5842-5846
47. Garfunkle J, Ezzili C, Rayl TJ, et al. Optimization of the central hetercycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem 2008;51:4392-4403
48. Edwards PD, Meyer EF, Vijayalakshmi J, et al. Design, synthesis, and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl alpha-ketobenzoxazoles, and the x-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-benzoxazole. J Am Chem Soc 1992;114:1854-1863
49. Hardouin C, Kelso MJ, Romero FA, et al. Structure-activity relationships of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem 2007;50:3359-3368
50. Apodaca R, Breitenbucher JG, Epperson MT, et al. Preparation of piperidinylbutanoyl oxazoles as fatty acid amide hydrolase (FAAH) modulators. WO2007061862; 2007
51. Apodaca R, Breitenbucher JG, Chambers A. Preparation of oxazolyl piperidinyl methanones as modulators of fatty acid amide hydrolase. WO2007140005; 2007
52. Timmons A, Seierstad M, Apodaca R, et al. Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett 2008;18:2109-2113
53. Tarzia G, Duranti A, Tontini A, et al. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem 2003;46:2352-2360
54. Mor M, Rivara S, Lodola A, et al. Cyclohexylcarbamic acid 3c-or 4c-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem 2004;47:4998-5008
55. Basso E, Duranti A, Mor M, et al. Tandem mass spectrometric data-FAAH inhibitory activity relationships of some carbamic acid O-aryl esters. J Mass Spectrom 2004;39:1450-1455
56. Tarzia G, Duranti A, Gatti G, et al. Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring. ChemMedChem 2006;1:130-139
57. Mor M, Lodola A, Rivara S, et al. Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of the biphenyl-3-yl alkylcarbamates. J Med Chem 2008;51:3487-3498
58. Vacondio F, Silva C, Lodola A, et al. Structure-property relationships of a class of carbamate based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability. ChemMedChem 2009;4:1495-1504
59. Clapper JR, Vacondio F, King AR, et al. A second generation of carbamate-based fatty acid amide hydrolase inhibitors with improved activity in vivo. ChemMedChem 2009;4:1505-1513
60. Mileni M, Kamtekar S, Wood DC, et al. Crystal structure of fatty acid amide hydrolase bound to the carbamate inhibitor URB597: discovery of a deacylating water molecule and insight into enzyme inactivation. J Mol Biol 2010;400:743-754
61. Saario SM, Poso A, Juvonen RO, et al. Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. J Med Chem 2006;49:4650-4656
62. Minkkila A, Myllymaki MJ, Saario SM, et al. The synthesis and biological evaluation of para-substitued phenolic N-alkylcarbamates as endocannabinoid hydrolyzing enzyme inhibitors. Eur J Med Chem 2009;44:2994-3008
63. Myllymaki MJ, Kasnanen H, Kataja AO, et al. Chiral 3-(4,5-dihydrooxazol- 2-yl) phenyl alkylcarbamates as novel FAAH inhibitors: insight into FAAH enantioselectivity by molecular docking and interaction fields. Eur J Med Chem 2009;44:4179-4191
64. Kasnanen H, Myllymaki MJ, Minkkila A, et al. 3-Heterocycl-phenyl N-alkylcarbamates as FAAH inhibitors: design, synthesis and 3D-QSAR studies. ChemMedChem 2010;5:213-231
65. Gattinoni S, Simone CD, Dallavalle S, et al. Enol carbamates as inhibitors of fatty acid amide hydrolase (FAAH) endowed with high selectivity for FAAH over the other targets of the endocannabinoid system. ChemMedChem 2010;5:357-360
66. Sit SY, Xie K. Preparation of bisarylimidazolyl fatty acid amide hydrolase inhibitors for treatment of pain. WO2002087569; 2002
67. Sit SY, Xie K, Deng H. Preparation of (hetero)aryl carbamates and oximes as fatty acid amide hydrolase inhibitors. WO2003065989; 2003
68. Sit SY, Conway C, Bertekap R, et al. Novel inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett 2007;17:3287-3291
69. Sit SY, Conway CM, Xie K, et al. Oxime carbamates-discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett 2010;20:1275-1277
70. Minetti P, Cabri W, Borsini F, et al. Preparation of oxime carbamoyl derivatives as modulators of fatty acid amides hydrolase. WO2009138416; 2009
71. Abouabdellah A, Gorlitzer J, Hamley P, et al. Alkylthiazolyl carbamates, their preparation and use as fatty acid amido hydrolase (FAAH) inhibitors for treating FAAH-related pathologies. WO2010010288; 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT00822744
72. Long JZ, Nomura DK, Vann RE, et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci USA 2009;106:20270-20275
73. Morera E, De Petrocellis L, Morera L, et al. Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands. Bioorg Med Chem Lett 2009;19:6806-6809
74. Ishii T, Sugane T, Maeda J, et al. Preparation of pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivatives as FAAH inhibitors. WO2006088075; 2006
75. Aoki S, Munakata R, Kawano N, et al. Preparation of azole compounds for treating neuropathic pain. WO2010007966; 2010
76. Ishii T, Sugane T, Munakata R, et al. Carbamate compound or salt thereof. WO2010053120; 2010
77. Alexander JP, Cravatt BF. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J Am Chem Soc 2006;128:9699-9704
78. Keith JM, Apodaca R, Xiao W, et al. Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett 2008;18:4838-4843
79. Ahn K, Johnson DS, Fitzgerald LR, et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 2007;46:13019-13030
80. Johnson DS, Ahn K, Kesten S, et al. Benzothiophene piperazine and piperidine urea inhibitors of fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett 2009;19:2865-2869
81. Wang JL, Bowen SJ, Schweitzer BA, et al. Structure based design of novel irreversible FAAH inhibitors. Bioorg Med Chem Lett 2009;19:5970-5974
82. Fay LK, Johnson DS, Lazerwith SE, et al. Preparation of (hetero)biaryl ether methylidenepiperidinyl ureas as fatty acid amide hydrolase (FAAH) inhibitors. WO2008047229; 2008
83. Meyers MJ, Pelc MJ, Thorarensen A. 4-[3-(Aryloxy)benzylidene]-3- methylpiperidine aryl carboxamide compounds useful as FAAH inhibitors and their preparation. WO2009127949; 2009
84. Fay LK, Johnson DS, Meyers MJ, et al. Ether benzylidene piperidine aryl carboxamide compounds as FAAH inhibitors and their preparation. WO2009127944; 2009
85. Meyers MJ, Pelc MJ, Thorarensen A, et al. 4-[3-(Aryloxy)benzylidene]-3- methylpiperidine 5-membered aryl carboxamide compounds as FAAH inhibitors and their preparation. WO2009127948; 2009
86. Meyers MJ, Pelc MJ, Schweitzer BA, et al. 4-Benzylidene-3- methylpiperidine aryl carboxamide compounds as FAAH inhibitors and their preparation. WO2009127946; 2009
87. Fay LK, Johnson DS, Meyers MJ, et al. Ether benzylidene piperidine 5-membered aryl carboxamide compounds as FAAH inhibitors and their preparation. WO2009127943; 2009
88. Long SA, Meyers MJ, Pelc MJ, et al. 7-Azaspiro[3.5]nonane-7-carboxamide compounds as modulators of fatty acid amide hydrolase. WO2010049841; 2010
89. Long SA, Meyers MJ, Pelc MJ, et al. 1-Oxa-8-azaspiro[4,5]decane-8- carboxamide compounds as FAAH inhibitors. WO2010058318; 2010. Available from: http://media.pfizer.com/files/investors/presentations/acr-102808-v2.pdf
90. Roughley S, Walls S, Hart T, et al. Azetidine derivatives as inhibitors of fatty acid amide hydrolase useful in the treatment of diseases and preparation and pharmaceutical compositions thereof. WO2009109743; 2009
91. Hart T, Macias AT, Benwell K, et al. Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett 2009;19:4241-4244
92. Even L, Hoornaert C. Derivatives of triazolopyridine carboxamides, particularly (piperazin-1-yl)(1,2,3-triazolo-[4,5-b]pyridin-1-yl)methanones and (piperidin-1-yl)(1,2,3-triazolo[4,5-b] pyridin-1-yl)methanones, their preparation and use as selective monoacyl glycerol lipase (MGL) inhibitors or mixed MGL and fatty acid amide hydrolase inhibitors. WO2008145839; 2008
93. Even L, Hoornaert C. Derivatives of triazolopyridine carboxamides, particularly (piperazin-1-yl)(1,2,3-triazolo-[4,5-b]pyridin-1-yl)methanones, their preparation and use as selective monoacyl glycerol lipase (MGL) inhibitors or mixed MGL and fatty acid amide hydrolase inhibitors. WO2008145843; 2008
94. Makriyannis A, Pandarinathan L, Zvonok N, et al. Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors. WO2009117444; 2009
95. Ishii T, Sugane T, Kakefuda A, et al. Preparation of piperazine-1- carboxamide and piperidine-1-carboxamide derivatives as inhibitors of fatty acid amide hydrolase (FAAH). WO2008023720; 2008
96. Minkkila A, Saario S, Kasnanen H, et al. Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem 2008;51:7057-7060
97. Behnke ML, Castro AC, Evans, CA, et al. Preparation of oxadiazolylphenylboronic acid derivatives and analogs for use as fatty acid amide hydrolase inhibitors. WO2009126691; 2009
98. Adams J, Behnke ML, Castro AC, et al. Preparation of arylboronates as inhibitors of fatty acid amide hydrolase. WO2008063300; 2008
99. Behnke ML, Castro AC, Evans CA, et al. Preparation of oxadiazolylphenylboronic acid derivatives and analogs for use as fatty acid amide hydrolase inhibitors. WO2009126691; 2009
100. Urbach A, Muccioli GG, Stern E, et al. 3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. Bioorg Med Chem Lett 2008;18:4163-4167
101. Feledziak M, Michaux C, Urbach A, et al. beta-Lactams derived from a carbapenem chiron are selective inhibitors of human fatty acid amide hydrolase versus human monoacylglycerol lipase. J Med Chem 2009;52:7054-7068
102. Wilmouth RC, Kassamally S, Westwood NJ, et al. Mechanistic insight into the inhibition of serine proteases by monocyclic lactams. Biochemistry 1999;38:7989-7998
103. Lin LS, Chang LL, Chobanian H, et al. Pyrazole derivatives useful as inhibitors of FAAH and their preparation and use in the treatment of diseases. WO2009151991; 2009
104. Lin LS, Chioda MD, Liu P, et al. Preparation of imidazole derivatives useful as inhibitors of FAAH. WO2009152025; 2009
105. Chobanian H, Lin LS, Liu P, et al. Preparation of oxazole derivatives as inhibitors of FAAH. WO2010017079; 2010
106. Kelly MG, Kincaid J, Gowlugari S, et al. Preparation of substituted naphthyridines as FAAH modulators. WO2009011904; 2009
107. Kaub C, Gowlugari S, Kincaid J, et al. Compounds useful as faah modulators and uses thereof. WO2010039186; 2010
108. Apodaca R, Breitenbucher JG, Chambers A, et al. Preparation of Aryl-hydroxyethylamino-pyrimidines and Triazines As Modulators of Fatty Acid Amide Hydrolase. WO 2009105220; 2009.
109. Ma Z, Gustin DJ, Li Y, et al. Identification of a potent, non-covalent series of fatty acid amide hydrolase (FAAH) inhibitors. Abstracts of Papers, 237th ACS National Meeting; Salt Lake City, UT, United States, 22-26 March, 2009; MEDI-105
110. Talley JJ, Sprott K, Pearson JP, et al. Indole compounds for treating pain, inflammation and other conditions. WO2008019357; 2008
111. Bartolini W, Cali BN, Chen B, et al. Useful indole compounds. WO2007070892; 2007. Available from: http://www.leaddiscovery.co.uk/trials/8266
112. Wang X, Sarris K, Kage K, et al. Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors. J Med Chem 2009;52:170-180
113. Minkkila A, Savinainen JR, Kasnanen H, et al. Screening of various hormone-sensitive lipase inhibitors as endocannabinoid-hydrolyzing enzyme inhibitors. ChemMedChem 2009;4:1253-1259
114. Learmonth DA, Kiss LE, Beliaev A, et al. 5-O-Substituted 3-N-phenyl-1,3,4-oxadiazolones as FAAH inhibitors and their preparation and use in the treatment of diseases. WO2009084970; 2009
115. Forster L, Ludwig J, Kaptur M, et al. 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A2 alpha and fatty acid amide hydrolase. Bioorg Med Chem 2010;18:945-952
116. Justinova Z, Mangieri RA, Bortolato M, et al. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry 2008:64:930-937
117. Maccarrone M. Endocannabinoids: friends and foes of reproduction. Progress in Lipid Research 2009;48:344-354
118. Lewis SE, Maccarrone M. Endocannabinoids, sperm biology and human fertility. Pharm Res 2009;60:126-131
119. Francavilla F, Battista N, Barbonetti A, et al. Characterization of the endocannabinoid system in human spermatozoa and involvement of transient receptor potential vanilloid 1 receptor in their fertilizing ability. Endocrinology 2009;150:4692-4700
120. Habayeb OM, Taylor AH, Finney M. Plasma anandamide concentration and pregnancy outcome in woman with threatened miscarriage. J Am Med Assoc 2008;299:1135-1136
121. Sun X, Wang H, Okabe M, et al. Genetic loss of FAAH compromises male fertility in mice. Biol Reprod 2009;80:235-242
122. Jesudason D, Wittert G. Endocannabinoid system in food intake and metabolic regulation. Curr Opin Lipidol 2008;19:344-348
123. Capasso R, Izzo AA. Gastrointestinal regulation of food intake: general aspects and focus on anandamide and oleoylethanolamide. J Neuroendocrin 2008;20(S1):39-46
124. Smith PJW, McQueen DS. Anandamide induces cardiovascular and respiratory reflexes via vasosensory nerves in the anaesthetized rat. Br J Pharmacol 2001;134:655-663
125. Hogestatt ED, Zygmunt PM. Cardiovascular pharmacology of anandamide. Prostaglandins, Leukot Essent Fatty Acids 2002;66:343-351
126. Pacher P, Batkai S, Osei-Hyiaman D, et al. Hemodynamic profile, responsiveness to anandamide and barareflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol 2005;289:H533-41
127. Batkai S, Pacher P, Ose-Hyiaman D, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004;110:1996-2002
128. Awumey EM, Howlett AC, Diz DI. Is there a role for anandamide in cardiovascular regulation? Insights from studies of endocannabinoid metabolism. Am J Physiol Heart Circ Physiol 2005;289:H520-1